Olema Pharmaceuticals Inc
OLMA
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.1B
Close$
$0.54
95.7% downside
Current Fair Value
95.7% downsideOvervalued by 95.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.10 Billion |
|---|---|
| Enterprise Value | $1.05 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.87 |
| Beta | 2 |
| Outstanding Shares | 102,800,098 |
Return
| Return on Equity | -38.53% |
|---|---|
| Return on Assets | -34.89% |
| Return on Invested Capital | -40.98% |
Valuation & Multiples
| P/E Ratio | -6.26 |
|---|---|
| PEG | -8.38 |
| Price to Sales | - |
| Price to Book Ratio | 3.16 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -5.31 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.53
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2403▼ 29.78% |
|---|---|
| Total Calls | 2,714,011▲ 156.21% |
| Total Puts | 652,100▲ 14.40% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 116.62%▲ 10.79% |
|---|---|
| Total Invested | $1.51B▼ 33.28% |
| Investors Holding | 219▲ 7.00% |
ESG Score
No data
About Olema Pharmaceuticals Inc
37 employeesOlema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is an o...